These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Quantitative Analysis Versus Visual Assessment of Neuromelanin MR Imaging for the Diagnosis of Parkinson's disease. Reimão S; Pita Lobo P; Neutel D; Guedes LC; Coelho M; Rosa MM; Ferreira J; Abreu D; Gonçalves N; Morgado C; Nunes RG; Campos J; Ferreira JJ J Parkinsons Dis; 2015; 5(3):561-7. PubMed ID: 26406136 [TBL] [Abstract][Full Text] [Related]
4. Magnetic resonance correlation of iron content with neuromelanin in the substantia nigra of early-stage Parkinson's disease. Reimão S; Ferreira S; Nunes RG; Pita Lobo P; Neutel D; Abreu D; Gonçalves N; Campos J; Ferreira JJ Eur J Neurol; 2016 Feb; 23(2):368-74. PubMed ID: 26518135 [TBL] [Abstract][Full Text] [Related]
5. Neuromelanin-sensitive magnetic resonance imaging features of the substantia nigra and locus coeruleus in de novo Parkinson's disease and its phenotypes. Wang J; Li Y; Huang Z; Wan W; Zhang Y; Wang C; Cheng X; Ye F; Liu K; Fei G; Zeng M; Jin L Eur J Neurol; 2018 Jul; 25(7):949-e73. PubMed ID: 29520900 [TBL] [Abstract][Full Text] [Related]
6. Substantia Nigra Neuromelanin as an Imaging Biomarker of Disease Progression in Parkinson's Disease. Fabbri M; Reimão S; Carvalho M; Nunes RG; Abreu D; Guedes LC; Bouça R; Lobo PP; Godinho C; Coelho M; Gonçalves NC; Rosa MM; Antonini A; Ferreira JJ J Parkinsons Dis; 2017; 7(3):491-501. PubMed ID: 28671143 [TBL] [Abstract][Full Text] [Related]
7. T1-weighted MRI shows stage-dependent substantia nigra signal loss in Parkinson's disease. Schwarz ST; Rittman T; Gontu V; Morgan PS; Bajaj N; Auer DP Mov Disord; 2011 Aug; 26(9):1633-8. PubMed ID: 21491489 [TBL] [Abstract][Full Text] [Related]
8. Changes in substantia nigra and locus coeruleus in patients with early-stage Parkinson's disease using neuromelanin-sensitive MR imaging. Ohtsuka C; Sasaki M; Konno K; Koide M; Kato K; Takahashi J; Takahashi S; Kudo K; Yamashita F; Terayama Y Neurosci Lett; 2013 Apr; 541():93-8. PubMed ID: 23428505 [TBL] [Abstract][Full Text] [Related]
9. Neuromelanin magnetic resonance imaging of locus ceruleus and substantia nigra in Parkinson's disease. Sasaki M; Shibata E; Tohyama K; Takahashi J; Otsuka K; Tsuchiya K; Takahashi S; Ehara S; Terayama Y; Sakai A Neuroreport; 2006 Jul; 17(11):1215-8. PubMed ID: 16837857 [TBL] [Abstract][Full Text] [Related]
10. Automated neuromelanin imaging as a diagnostic biomarker for Parkinson's disease. Castellanos G; Fernández-Seara MA; Lorenzo-Betancor O; Ortega-Cubero S; Puigvert M; Uranga J; Vidorreta M; Irigoyen J; Lorenzo E; Muñoz-Barrutia A; Ortiz-de-Solorzano C; Pastor P; Pastor MA Mov Disord; 2015 Jun; 30(7):945-52. PubMed ID: 25772492 [TBL] [Abstract][Full Text] [Related]
11. Simultaneous imaging of locus coeruleus and substantia nigra with a quantitative neuromelanin MRI approach. Chen X; Huddleston DE; Langley J; Ahn S; Barnum CJ; Factor SA; Levey AI; Hu X Magn Reson Imaging; 2014 Dec; 32(10):1301-6. PubMed ID: 25086330 [TBL] [Abstract][Full Text] [Related]
12. An investigation of neuromelanin distribution in substantia nigra and locus coeruleus in patients with Parkinson's disease using neuromelanin-sensitive MRI. Liu Q; Wang P; Liu C; Xue F; Wang Q; Chen Y; Hou R; Chen T BMC Neurol; 2023 Aug; 23(1):301. PubMed ID: 37580712 [TBL] [Abstract][Full Text] [Related]
13. Three-dimensional neuromelanin-sensitive magnetic resonance imaging of the substantia nigra in Parkinson's disease. Prasad S; Stezin A; Lenka A; George L; Saini J; Yadav R; Pal PK Eur J Neurol; 2018 Apr; 25(4):680-686. PubMed ID: 29341412 [TBL] [Abstract][Full Text] [Related]
14. Neuromelanin related ultra-high field signal intensity of the locus coeruleus differs between Parkinson's disease and controls. Wolters AF; Heijmans M; Priovoulos N; Jacobs HIL; Postma AA; Temel Y; Kuijf ML; Michielse S Neuroimage Clin; 2023; 39():103479. PubMed ID: 37494758 [TBL] [Abstract][Full Text] [Related]
15. A distinct neuromelanin magnetic resonance imaging pattern in parkinsonian multiple system atrophy. Simões RM; Castro Caldas A; Grilo J; Correia D; Guerreiro C; Pita Lobo P; Valadas A; Fabbri M; Correia Guedes L; Coelho M; Rosa MM; Ferreira JJ; Reimão S BMC Neurol; 2020 Nov; 20(1):432. PubMed ID: 33243166 [TBL] [Abstract][Full Text] [Related]
16. Differentiation of early-stage parkinsonisms using neuromelanin-sensitive magnetic resonance imaging. Ohtsuka C; Sasaki M; Konno K; Kato K; Takahashi J; Yamashita F; Terayama Y Parkinsonism Relat Disord; 2014 Jul; 20(7):755-60. PubMed ID: 24768616 [TBL] [Abstract][Full Text] [Related]
17. Association of Locus Coeruleus and Substantia Nigra Pathology With Cognitive and Motor Functions in Patients With Parkinson Disease. Prasuhn J; Prasuhn M; Fellbrich A; Strautz R; Lemmer F; Dreischmeier S; Kasten M; Münte TF; Hanssen H; Heldmann M; Brüggemann N Neurology; 2021 Sep; 97(10):e1007-e1016. PubMed ID: 34187859 [TBL] [Abstract][Full Text] [Related]
18. Optimizing neuromelanin contrast in the substantia nigra and locus coeruleus using a magnetization transfer contrast prepared 3D gradient recalled echo sequence. Liu Y; Li J; He N; Chen Y; Jin Z; Yan F; Haacke EM Neuroimage; 2020 Sep; 218():116935. PubMed ID: 32413460 [TBL] [Abstract][Full Text] [Related]
19. A Comparison of Substantia Nigra T1 Hyperintensity in Parkinson's Disease Dementia, Alzheimer's Disease and Age-Matched Controls: Volumetric Analysis of Neuromelanin Imaging. Moon WJ; Park JY; Yun WS; Jeon JY; Moon YS; Kim H; Kwak KC; Lee JM; Han SH Korean J Radiol; 2016; 17(5):633-40. PubMed ID: 27587951 [TBL] [Abstract][Full Text] [Related]
20. Spatiotemporal changes in substantia nigra neuromelanin content in Parkinson's disease. Biondetti E; Gaurav R; Yahia-Cherif L; Mangone G; Pyatigorskaya N; Valabrègue R; Ewenczyk C; Hutchison M; François C; Arnulf I; Corvol JC; Vidailhet M; Lehéricy S Brain; 2020 Sep; 143(9):2757-2770. PubMed ID: 32856056 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]